Chen Fen-hua, Wang Qing-wen, Pan Si-nian, Chen Hui-qin, Ji Jing-zhi, He Zheng-xian
Department of Pediatrics, The Third Affiliated Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou 510630, China.
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2004 Mar;18(1):76-9.
To investigate the effective therapeutic method of human cytomegalovirus (HCMV) hepatitis in children.
Twenty-five children with HCMV hepatitis were randomly assigned to a treated group (n=13) or a control group (n=12). Both groups were treated with prednisone, glucurone, luminal and Xiaoyanlidanpian. But the treated group was given ganciclovir (GCV) + intravenous immunoglobulin (IVIG) in addition. Each infant of the two groups was checked for blood routine, liver function and HCMV copy numbers on admission and before discharge. They were seen at the third, sixth and ninth month after discharge. On each visit blood specimens were collected for HCMV copy numbers (fluorescence quantitative PCR, FQ-PCR).
The viral load of the treated group decreased significantly. A significant difference in viral copy numbers was found between the two groups on admission, discharge, and third, sixth and ninth month after discharge (P less than 0.001). The number of HCMV DNA copy fell to 10(3) copies/ml on discharge while that of the control group fell to the same level after the third month. The differences between the two groups in the length of hospitalization, time of initial jaundice disappearance and complete disappearance were statistically significant (P less than 0.05). The need for transfusion in the treated group was significantly less than that in the control group (chi-square=4.012, P less than 0.05).
Combination of GCV with a high dosage of IVIG to treat HCMV active infection could decrease viral load remarkably; The duration of disease, severity of symptoms, degree of anemia and the need for blood transfusion were reduced. No adverse effects related to the combination of GCV with IVIG therapy were observed.
探讨儿童人巨细胞病毒(HCMV)肝炎的有效治疗方法。
25例HCMV肝炎患儿随机分为治疗组(n = 13)和对照组(n = 12)。两组均给予泼尼松、葡醛内酯、鲁米那及消炎利胆片治疗。但治疗组加用更昔洛韦(GCV)+静脉注射免疫球蛋白(IVIG)。两组患儿入院时及出院前均检查血常规、肝功能及HCMV拷贝数。出院后第3、6、9个月进行随访。每次随访时采集血标本检测HCMV拷贝数(荧光定量PCR,FQ-PCR)。
治疗组病毒载量显著下降。两组在入院时、出院时及出院后第3、6、9个月的病毒拷贝数有显著差异(P < 0.001)。治疗组出院时HCMV DNA拷贝数降至10³拷贝/ml,而对照组在第3个月后降至同一水平。两组在住院时间、黄疸开始消退时间及完全消退时间方面的差异有统计学意义(P < 0.05)。治疗组输血需求明显少于对照组(χ² = 4.012,P < 0.05)。
GCV联合大剂量IVIG治疗HCMV活动性感染可显著降低病毒载量;缩短病程,减轻症状严重程度、贫血程度及减少输血需求。未观察到与GCV联合IVIG治疗相关的不良反应。